5 results
Primary objective:• To investigate whether Enhanced programming is safe for primary and secondary prevention patientsSecondary objectives:• Investigate the impact of Enhanced programming on adverse events (related to ICD shock with consequences and…
Primary objective:To determine the MTD/recommended dose for further study of oral LOXO-292 in patients with advanced solid tumors, including RET-fusion NSCLC, MTC, and other tumors with increased RET activity.Secondary objectives:* To determine the…
The objectives of STIMO-2 are to demonstrate the safety and feasibility and to obtain preliminary evidence on the effectiveness of mobility rehabilitation facilitated by TESS to improve neurological recovery when this intervention is delivered in…
Primary* To compare TFFS of patients with progressive, advanced, kinase inhibitor naïve, RET-mutant MTC treated with LOXO-292 versus cabozantinib or vandetanib.Secondary* To compare other efficacy outcomes, based on RECIST 1.1 criteria, observed in…
To compare PFS of patients with progressive, advanced, kinase inhibitor naïve, RET-mutant MTC treated with selpercatinib versus cabozantinib or vandetanib.